The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen
- PMID: 2138051
The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen
Abstract
The efficacy of once-a-day cilazapril (a new long acting converting enzyme inhibitor) therapy for the 24 h control of hypertension and its effects on the renin-angiotensin axis were investigated. Twenty-four uncomplicated hypertensive patients whose sitting diastolic blood pressures remained within 94 to 114 mmHg after four weeks of placebo were randomly assigned on a double-blind basis to receive either continued placebo or cilazapril therapy at a single dose of 1.25, 2.5 or 5.0 mg/day for a further four weeks. At the end of weeks 4 and 8, systolic and diastolic blood pressures and heart rates were recorded, supine and standing, at 0, 2, 4, 6, 9, 12 and 24 h following a single dose of drug. At the same times, blood was withdrawn for determination of plasma renin activity and aldosterone. Supine and erect systolic and diastolic blood pressures were lowered to normotensive levels with an optimal response being achieved at a dose of 2.5 mg/day. Supine and erect heart rates were unchanged with respect to drug dosage, and the reflex increase in heart rate and diastolic blood pressure on changing from supine to erect posture was maintained in all groups. Maximum antihypertensive efficacy was from 2 to 6 h after drug ingestion. There were no changes in resting aldosterone, but plasma renin activity was increased at all drug dosages. A single 2.5 mg dose of cilazapril provides blood pressure control for a 24 h period. Cilazapril does not appear to interfere with the reflex autonomic responses to postural change.
Similar articles
-
Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.Drugs. 1991 May;41(5):799-820. doi: 10.2165/00003495-199141050-00008. Drugs. 1991. PMID: 1712710 Review.
-
Cilazapril inhibits vascular responses to baroreflex-stimulated sympathetic neural activity in hypertensive patients.Can J Cardiol. 1990 Jan-Feb;6(1):9-14. Can J Cardiol. 1990. PMID: 2138049 Clinical Trial.
-
Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension.J Cardiovasc Pharmacol. 1988 Feb;11(2):230-4. J Cardiovasc Pharmacol. 1988. PMID: 2452319
-
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers.J Cardiovasc Pharmacol. 1987 Jan;9(1):39-44. J Cardiovasc Pharmacol. 1987. PMID: 2434792 Clinical Trial.
-
Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function.J Cardiovasc Pharmacol. 1988 Feb;11(2):242-9. J Cardiovasc Pharmacol. 1988. PMID: 2452321
Cited by
-
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003823. doi: 10.1002/14651858.CD003823.pub2. Cochrane Database Syst Rev. 2008. PMID: 18843651 Free PMC article.
-
Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.Drugs. 1991 May;41(5):799-820. doi: 10.2165/00003495-199141050-00008. Drugs. 1991. PMID: 1712710 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical